根除治疗后原发性胃弥漫性大B细胞淋巴瘤的系列回归：一例报告。
Serial regression of primary gastric diffuse large B cell lymphoma after eradication therapy: A case report.
作者信息
Lyu Ting-Wei, Yu Shan-Chi, Lin Chien-Chin
机构信息
Division of Hematology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan.
Department of Pathology National Taiwan University Hospital Taipei Taiwan.
出版信息
Clin Case Rep. 2024 Aug 5;12(8):e9235. doi: 10.1002/ccr3.9235. eCollection 2024 Aug.
KEY CLINICAL MESSAGE
Primary gastric diffuse large B-cell lymphoma (DLBCL), a rare malignancy linked to () infection, in this case regressed to low-grade lymphoma and then achieved complete remission after eradication (E), highlighting this unique interim change and the potential of E as an effective treatment for early-stage cases.
ABSTRACT
Primary gastric diffuse large B-cell lymphoma (DLBCL) is a rare malignancy. Like gastric mucosa-associated lymphoid tissue (MALT) lymphoma, infection is implicated in lymphomagenesis and has thus emerged as a therapeutic target. Studies have demonstrated the sustained efficacy of eradication alone for limited-stage primary gastric DLBCL. This report presents the case of a 53-year-old woman with stage IE gastric DLBCL who received triple therapy for eradication and experienced an interim histological transformation to MALT lymphoma, ultimately achieving complete pathologic remission. eradication therapy may represent a viable treatment option for patients with early-stage primary gastric DLBCL.
关键临床信息
原发性胃弥漫性大B细胞淋巴瘤（DLBCL）是一种与（）感染相关的罕见恶性肿瘤，在此病例中，其退化为低级别淋巴瘤，然后在（）根除后实现完全缓解，突出了这种独特的中间变化以及根除作为早期病例有效治疗方法的潜力。
摘要
原发性胃弥漫性大B细胞淋巴瘤（DLBCL）是一种罕见的恶性肿瘤。与胃黏膜相关淋巴组织（MALT）淋巴瘤一样，（）感染与淋巴瘤的发生有关，因此已成为治疗靶点。研究表明，单独根除（）对局限性原发性胃DLBCL具有持续疗效。本报告介绍了一名53岁患有IE期胃DLBCL的女性患者，她接受了根除（）的三联疗法，并经历了组织学上向MALT淋巴瘤的中间转变，最终实现了完全病理缓解。根除（）疗法可能是早期原发性胃DLBCL患者的一种可行治疗选择。
Zotero 插件